> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly EUA for Monoclonal Antibodies Expanded
- URL: https://www.fdaweb.com/lilly-eua-for-monoclonal-antibodies-expanded/
- Published: 2021-12-03T12:00:00.000Z
- Updated: 2026-09-14T17:24:28.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150697

FDA has revised an Eli Lilly [emergency use authorization](http://email.prnewswire.com/ls/click?upn=3slWLw94I3jq-2B-2FedjFNgZAmdierth9sDznGHUIlSHO9lzq0tGktuJ7wJ0dAAotAT1T3Jcnd6FGluDdKDbM9dtQ-3D-3DdORK%5FxCGFIN3nMOPWun4BAdUrZI6NUVIWPuhGNPih1t9UspWUawZ-2BSsLNM-2FdqNsHgZvBOEKwAYT0ZV6ACSUaakHFqiGQRQghjPbvf6CAm-2BEhZX7Dzjqv5xHqktBtRs4MP6gl43Y6j5IBcRudV9HnyiZg-2FJg2Rgo43ctU19J2jpGDyw-2BNlmD7dWAvWjnVhpRLwRGQn9W-2FjA-2FFNnzVFZUo1WaMSgUut02BDBh0M8jBVMzGR6pLwLQqY9JJgNM7i7k6h3KbwfiGyTfmt2LPeO1L4061P-2BM-2BYtBiNJ5yekwY6m1jmmFIYwxN-2BqqXecHwoGW0IqeF6ctdBxg4Yjr9HzGtWU9SxAfSIQnG8ZOkZSVuVX37w7CUDS9pV86-2B3BytS6btQucSZ&ref=fdaweb.com) (EUA) for bamlanivimab and etesevimab to be used in younger pediatric patients than previously authorized for treating mild to moderate Covid-19\. Previously, the monoclonal antibodies’ combination use was authorized for pediatric patients 12 years of age and older, and the new authorization covers all younger pediatric patients, including newborns, who have a positive Covid-19 test and are at high risk for progression to severe disease, according to an [FDA release](https://www.fda.gov/news-events/press-announcements/fda-expands-authorization-two-monoclonal-antibodies-treatment-and-post-exposure-prevention-covid-19?ref=fdaweb.com).